Cargando…

Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer

Each patient’s cancer consists of multiple cell subpopulations that are inherently heterogeneous and may develop differing phenotypes such as drug sensitivity or resistance. A personalized treatment regimen should therefore target multiple oncoproteins in the cancer cell populations that are driving...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Liye, Bulanova, Daria, Oikkonen, Jaana, Häkkinen, Antti, Zhang, Kaiyang, Zheng, Shuyu, Wang, Wenyu, Erkan, Erdogan Pekcan, Carpén, Olli, Joutsiniemi, Titta, Hietanen, Sakari, Hynninen, Johanna, Huhtinen, Kaisa, Hautaniemi, Sampsa, Vähärautio, Anna, Tang, Jing, Wennerberg, Krister, Aittokallio, Tero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Case Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574973/ https://www.ncbi.nlm.nih.gov/pubmed/34343245 http://dx.doi.org/10.1093/bib/bbab272

Ejemplares similares

Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer
por: Zhang, Kaiyang, et al.
Publicado: (2022)

PRISM: recovering cell-type-specific expression profiles from individual composite RNA-seq samples
por: Häkkinen, Antti, et al.
Publicado: (2021)

QuantISH: RNA in situ hybridization image analysis framework for quantifying cell type-specific target RNA expression and variability
por: Jamalzadeh, Sanaz, et al.
Publicado: (2022)

Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer
por: Oikkonen, Jaana, et al.
Publicado: (2019)

Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrence
por: Marchi, Giovanni, et al.
Publicado: (2023)

Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
por: Pikkusaari, Sanna, et al.
Publicado: (2023)

A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids
por: Senkowski, Wojciech, et al.
Publicado: (2023)

Quantification of cell death and proliferation of patient-derived ovarian cancer organoids through 3D imaging and image analysis
por: Skorda, Aikaterini, et al.
Publicado: (2023)

FUNGI: FUsioN Gene Integration toolset
por: Cervera, Alejandra, et al.
Publicado: (2021)

Improved detection of differentially represented DNA barcodes for high‐throughput clonal phenomics
por: Akimov, Yevhen, et al.
Publicado: (2020)

qSNE: quadratic rate t-SNE optimizer with automatic parameter tuning for large datasets
por: Häkkinen, Antti, et al.
Publicado: (2020)

Agile workflow for interactive analysis of mass cytometry data
por: Casado, Julia, et al.
Publicado: (2020)

TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples
por: He, Liye, et al.
Publicado: (2015)

Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status
por: Roering, Pia, et al.
Publicado: (2022)

Author Correction: Virtual clinical trials identify effective combination therapies in ovarian cancer
por: Kozłowska, Emilia, et al.
Publicado: (2020)

Virtual clinical trials identify effective combination therapies in ovarian cancer
por: Kozłowska, Emilia, et al.
Publicado: (2019)

What is synergy? The Saariselkä agreement revisited
por: Tang, Jing, et al.
Publicado: (2015)

Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance
por: Pietilä, Elina A., et al.
Publicado: (2021)

Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer
por: Perez-Villatoro, Fernando, et al.
Publicado: (2022)

Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
por: Yadav, Bhagwan, et al.
Publicado: (2015)

Corrigendum to “Searching for drug synergy in complex dose–response landscapes using an interaction potency model” [Comput. Struct. Biotechnol. J. 13 (2015) 504–513]
por: Yadav, Bhagwan, et al.
Publicado: (2017)

A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening
por: Gupta, Abhishekh, et al.
Publicado: (2020)

Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach
por: Ali, Mehreen, et al.
Publicado: (2018)

A Subset of Secreted Proteins in Ascites Can Predict Platinum-Free Interval in Ovarian Cancer
por: Carroll, Molly J., et al.
Publicado: (2022)

Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality
por: Jukonen, Joonas, et al.
Publicado: (2021)

miQC: An adaptive probabilistic framework for quality control of single-cell RNA-sequencing data
por: Hippen, Ariel A., et al.
Publicado: (2021)

Systematic identification of feature combinations for predicting drug response with Bayesian multi-view multi-task linear regression
por: Ammad-ud-din, Muhammad, et al.
Publicado: (2017)

POIBM: batch correction of heterogeneous RNA-seq datasets through latent sample matching
por: Holmström, Susanna, et al.
Publicado: (2022)

Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways
por: Tang, Jing, et al.
Publicado: (2013)

Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells
por: Jaiswal, Alok, et al.
Publicado: (2017)

Novel Screening Method Identifies PI3Kα, mTOR, and IGF1R as Key Kinases Regulating Cardiomyocyte Survival
por: Elmadani, Manar, et al.
Publicado: (2019)

A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer
por: Salminen, Liina, et al.
Publicado: (2021)

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
por: Gautam, Prson, et al.
Publicado: (2016)

From drug response profiling to target addiction scoring in cancer cell models
por: Yadav, Bhagwan, et al.
Publicado: (2015)

Multi‐modal meta‐analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor
por: Jaiswal, Alok, et al.
Publicado: (2021)

Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors
por: Cichonska, Anna, et al.
Publicado: (2017)

Intrahepatic cholestasis of pregnancy: observational study of the treatment with low-dose ursodeoxycholic acid
por: Joutsiniemi, Titta, et al.
Publicado: (2015)

Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells’ sensitivity to paclitaxel
por: Tambe, Mahesh, et al.
Publicado: (2016)

Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose–response data
por: Mpindi, John-Patrick, et al.
Publicado: (2015)

Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer
por: Facciotto, Chiara, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_svq4068h0d1on6fd6nr2s1aj28